| Type 2 Diabetes Mellitus |
1 |
1 |
| Hypoglycemia |
0 |
0.47 |
| Meta-Analysis |
0 |
0.47 |
| GLP-1 Receptor Agonist |
0 |
0.41 |
| Weight Loss |
0 |
0.4 |
| Weight Management |
0 |
0.39 |
| Electronic Health Record (EHR) |
0 |
0.3 |
| Electronic Medical Record |
0 |
0.27 |
| Receptors |
0 |
0.27 |
| SGLT2 Inhibitor |
0 |
0.27 |
| Type 1 Diabetes Mellitus |
0 |
0.24 |
| Adherence |
0 |
0.2 |
| Adverse Effects |
0 |
0.2 |
| Diabetes Mellitus |
0 |
0.2 |
| Hypertension |
0 |
0.2 |
| Patient Safety |
0 |
0.2 |
| Thyroid Disease |
0 |
0.16 |
| Head and Neck Cancer |
0 |
0.15 |
| Heart Failure (HF) |
0 |
0.14 |
| Blood |
0 |
0.13 |
| Cardiovascular Risk Management |
0 |
0.13 |
| Medullary Thyroid Cancer |
0 |
0.12 |
| Thyroid Cancer |
0 |
0.11 |
| Renal Disease |
0 |
0.09 |
| Abdominal Infection |
0 |
0.07 |
| Antihypertensive Agents |
0 |
0.07 |
| Board Certification |
0 |
0.07 |
| Cancer |
0 |
0.07 |
| Cardiovascular disease |
0 |
0.07 |
| Cerebrovascular Accident |
0 |
0.07 |
| Data Collection |
0 |
0.07 |
| Dehydration |
0 |
0.07 |
| Diabetic Ketoacidosis |
0 |
0.07 |
| Drug Reaction |
0 |
0.07 |
| Heart |
0 |
0.07 |
| Hemodynamics |
0 |
0.07 |
| Hemoglobin |
0 |
0.07 |
| Kidney |
0 |
0.07 |
| Multiple Endocrine Neoplasia (MEN) |
0 |
0.07 |
| Multiple Sclerosis |
0 |
0.07 |
| Pancreatitis |
0 |
0.07 |
| Sulfonylureas |
0 |
0.07 |
| Thyroid |
0 |
0.07 |